Sofia Michael J.

Sofia Michael J. serves as the Chief Scientific Officer at Arbutus Biopharma Corp, a firm focused on developing innovative therapeutics for viral diseases. Her role involves overseeing the company's scientific strategy and research initiatives. Recent SEC Form 4 filings reveal a distinct trading pattern, with a total of three disclosures related to Arbutus Biopharma Corp (ABUS) as of February 5, 2024, primarily involving sale activity. The largest disclosed move was a grant/exercise valued at approximately $1.1 million on the same date.